PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
Clinical trial NCT05137886 · UNKNOWN
Trial details
- NCT number
- NCT05137886
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-01
- Primary completion
- 2024-01-01
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.